News and Comments

Pharmacyclics: When the Power of Biotechs' Pipelines Overshadows the Market’s influence on the Firms' Values.

  Thursday, February 23, 2012

Pharmacyclic’s (PCYC) story is one of a few where the power of pipeline drugs has overshadowed the stock market’s technical influence on the biotech companies’ values. In other words, in the case of Pharmacyclics, investors should be looking for something extraordinary in the firm’s pipeline, in its choices of its programs, in its plans and strategies in developing its pipeline products and its capability of executing its plans and reaching its goals. Pharmacyclics’ Bruton’s tyrosine Kinase (BTK) inhibitor PCI-32765 therapeutic is unique. In December 2011, Pharmacyclics was granted U.S. patent that testifies to the drug’s exceptionality. It is, indeed, the first irreversible inhibitor in the BTK zone.     More...

Illumina, Roche and Fairness

  Thursday, February 09, 2012

Illumina (ILMN) is occupying the center stage these days. Roche’s persistent attempts to acquire ILMN, has opened investors’ eyes on the importance of this firm’s technology in moving away from the road of stagnation to that of innovation. Innovation is the insurance that guarantees the survival and growth of the drug companies in the future that has already begun. Illumina’s technologies and marketed state-of-the-art sequencers and gene analyzers have been a major contributor to the flourishing of information about the origins of diseases at the molecular level.  This capability, which lured Roche, was overlooked by Wall Street investors who have recently caused a selloff in the stock for theorized reasons. The real value of Illumina resides in its indispensability as the cornerstone of future advancement in medical diagnosis and treatment. With all the new-targeted drugs on the market and in the firms’ pipelines, the current diagnostic and treatment statuses are still far from perfect. More...

Recent Postings



Onyx (ONXX) Exelixis (EXEL) NEKTAR (NKTR)) Gilead (GILD) KERYX (KERX) ISIS (ISIS) Cytokinetics (CYTK) CEMPRA (CEMP) SYNTA (SNTA) ImmunoGen (IMGN) ZALTRAP™ Regeneron (REGN) Alnylam (ALNY) Valeant Pharmaceuticals International (VRX) Spike Therapeutics (ONCE) Anacor (ANAC) Agenus (AGEN Bristol-Myers Squibb (BMY) Sarepta (SRPT) Adaptimmune (ADAP) ARGOS (ARGS) SERES THERAPEUTICS (MCRB) Ariad (ARIA) Roche (ROCHE) GUARDIAN HEALTH Anadys (ANDS) VANDA (VNDA) Multiple Myeloma NANTKWEST (NK) TOKAI (TKAOI) Biocryst (BCRX) MODERNA Trastuzumab-DM1 SUNESIS PHARMACEUTICALS (SNSS) Intermune (ITMN) ACADIA (ACAD) AGOS (ARGS) Ridaforolimus Human Genome Sciences (HGSI) Bellicum (BLCM) C4 Therapeutics Intercept (ICPT) Tysabri GlaxoSmithKline (GSK) Inovio (INO) PORTOLA (PTLA) Prosensa (RNA) Dynavax (DVAX) Endometrial Cancer Ziofpharm (ZIOP) PTC Therapeutics (PTCT) galapagos (GLPG) Incyte (INCY) Xoma (XOMA) Abbott Laboratories (ABT) Illumina (ILMN) Editas (EDIT) ADVENTRIX (ANX) KITE (KITE) Sanofi (SNA) Aimmune Therapeutics (AIMT) CompuGen (CGEN) Amgen (AMGN) Ocular Therapeutix (OCUL) REGULUS (RGLS) Zerenex ARCA (ABIO) Prolor Biotech (PBTH) Biogen Idec (BIIB) Jazz Pharmaceuticals (JAZZ) Ionis (IONS) Vertex (VRTX) HALOZYME (HALO) Sanofi-Aventis (SAN) Global Cell Therapeutics (GBT) JOUNCE THERAPEUTICS (JNCE) Rapamune Merck (MRK) Micromet (MITI) Agenus (AGEN) Sanofi (SNY) Genentech AERIE PHARMACEUTICALS INNOVIVA (INVA) Human Longevity (HLI) NOVOCURE (NVCR) Alder Biopharmaceuticals (ALDR) ABBVIE (ABBV) Array Pharmaceuticals (ARRY) LEXICON (LXRX) RenenxBio (RGNX) Pluristem (PSTI) Sequenom (SQNM) AstraZeneca (AZN) CRISPR Therapeutics (CRSP) Auspex (ASPX) OncoCyte (OCX) OSI (OSIP) Elan (ELN) Roche (RHHBY) Benlysta (belimumab) Idenix (IDIX) BIOMARIN (BMRN) Dendreon (DNDN) Herceptin Galena (GALE) Sangamo (SGMO) Vitae Pharmaceuticals (VTAE) Theravance (THRX) Telaprevir Seattle Genetics (SGEN) Mirati Therapeutics (MRTX) IDERA (IDRA) Revlimid (lenolidamide) Velcade (bortezomib) JUNO (JUNO) Advaxis (ADXS) Intrexon (XON) Theravance Bio Pharma (TBPH)